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Abstract 
Objective: Low-grade chronic inflammation is one potential mechanism underlying the well-
established association between major depressive disorder (MDD) and increased 
cardiovascular morbidity. Both aspirin and statins have anti-inflammatory properties, which may 
contribute to their preventive effect on cardiovascular diseases. Previous studies on the 
potentially preventive effect of these drugs on depression have provided inconsistent results. 
The aim of the present paper was to assess the prospective association between regular aspirin 
or statin use and the incidence of MDD.  
Method: This prospective cohort study included 1’631 subjects (43.6% women, mean age 51.7 
years), randomly selected from the general population of an urban area. Subjects underwent a 
thorough physical evaluation as well as semi-structured interviews investigating DSM-IV mental 
disorders at baseline and follow-up (mean duration 5.2 years). Analyses were adjusted for a 
wide array of potential confounders.  
Results: Our main finding was that regular aspirin or statin use at baseline did not reduce the 
incidence of MDD during follow-up, regardless of sex or age (hazard ratios, aspirin: 1.19; 
95%CI, 0.68-2.08; and statins: 1.25; 95%CI, 0.73-2.14; respectively). 
Limitations: Our study is not a randomized clinical trial and could not adjust for all potential 
confounding factors, information on aspirin or statin use was collected only for the 6 months 
prior to the evaluations, and the sample was restricted to subjects between 35 and 66 years of 
age. 
Conclusion: Our data do not support a large scale preventive treatment of depression using 
aspirin or statins in subjects aged from 35 to 66 years from the community. 
Key words: Major depressive disorder; aspirin; statins; inflammation; population-based study; 
longitudinal study. 
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Introduction 
Aspirin and statins are commonly used preventive treatments against cardiovascular diseases 
(CVD). Aside from the anti-platelet aggregation activity of aspirin and the lipid-lowering function 
of statins, these medications have been postulated to have anti-inflammatory properties 
(Antithrombotic Trialists et al., 2009; Antonopoulos et al., 2012). Depression has been found to 
be associated with an increased cardiovascular risk (Baune et al., 2012; Glaus et al., 2013; 
Penninx et al., 2013) and low-grade chronic inflammation is a possible mechanism that could 
underlie this association (Baune et al., 2012). Hence, it has been suggested that the regular use 
of aspirin or statins could be protective against depression (Berk et al., 2013; Stafford and 
Berk,2011; While and Keen, 2012; Parsaik et al., 2014). 
To our knowledge, the potential association between regular aspirin use and the development of 
major depressive disorder (MDD) has only been assessed in two Australian community studies 
(Almeida et al., 2010; Almeida et al., 2012; Pasco et al., 2010). One of them, a prospective 
study in women, found exposure to aspirin or statins (pooled) to be associated with a lower 
incidence of MDD over a period of 10 years (Pasco et al., 2010). The other one, a cross-
sectional survey in older men, showed past but not current aspirin use to be associated with a 
higher prevalence of depression in the whole sample (Almeida et al., 2010), whereas 
subsequent analyses in a subsample revealed an interaction between aspirin use and the total 
homocystein (tHcy) level, indicating a reduced risk of depression only in aspirin users with a 
high tHcy level (Almeida et al., 2012). Regarding statins, a review of five randomized clinical 
trials (RCTs) and three observational studies provided mostly negative evidence for an 
association between these drugs and depressive symptoms (While and Keen, 2012), with 
negative results from all RCTs and only support for a protective effect of statins in one (Young-
Xu et al., 2003) out of the three observational studies. In contrast, a recent meta-analysis of 
seven observational studies, which among the studies of the previous review only included the 
study of Young-Xu et al. (2003), documented a protective effect of statins against the 
development of depression (Parsaik et al., 2014). Moreover, a prospective community study of 
4 
 
elderly subjects not included in this meta-analysis revealed an interaction between sex and the 
effect of statins, with a preventive effect of these drugs on depressive symptoms over a 1.5-year 
period in women only (Feng et al., 2010). Finally, a recent register-based study of the Swedish 
population older than 40 years found differential associations for specific types of statins with 
depression: simvastatin was associated with a decreased risk and atorvastatin with an 
increased risk of depression (Redlich et al., 2014). The inconsistent results across studies are 
likely to be due to the large methodological variance (design, type of sample, length of follow-
up, definition and assessment of depression, number and measurement of covariates) and 
methodological limitations including short follow-up periods particularly in the RCTs, small 
sample sizes, adjustment for physical covariates using self-reported rather than measured 
physical conditions and inaccurate assessment of depression. Indeed, with the exception of the 
studies of Pasco et al. (Pasco et al., 2010) and Stafford et al. (Stafford and Berk, 2011), 
depression was generally assessed through rating scales rather than structured interviews. 
These rating scales do not take into account the frequent occurrence of comorbid mental 
disorders and generally suffer from low positive predictive value (proportion of positively 
screened subjects among those who are truly affected as determined by a gold standard, i.e. in 
psychiatry a structured diagnostic interview) (Myers and Weissman, 1980; Roberts and Vernon, 
1983; Thomas et al., 2001). Moreover, the large majority of studies determined the effect of 
statins on the evolution of mood symptoms rather than their potentially preventive effect on the 
incidence of MDD. Hence, the aim of the present paper was to assess the prospective 
association between regular aspirin or statin use and the incidence of MDD according to a 
structured diagnostic interview during a 5.2-year follow-up period in a large community sample 
with adjustment for a wide array of measured potentially confounding factors. Given previous 
findings of interactions between exposure to aspirin or statins and sex or the tHcy level 
regarding the incidence of MDD, we also tested the effects of sex or the tHcy level on the 
associations between aspirin or statin treatment and the subsequent risk of MDD. 
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Method 
Study sample 
The data of the present paper stemmed from CoLaus|PsyCoLaus (Firmann et al., 2008; Preisig 
et al., 2009), a cohort study designed to prospectively assess the associations between mental 
disorders and CVD or cardiovascular risk factors (CVRFs) in the community. The sample was 
randomly selected from the civil register of the city of Lausanne (Switzerland) in 2003. Sixty-
seven percent of the 35 to 66 year-old participants (n=5’535) who underwent the physical exam 
between 2003 and 2006 also accepted the psychiatric evaluation, which resulted in a sample of 
3’719 individuals (Preisig et al., 2009). In order to establish the incidence of MDD during the 
follow-up we had to exclude 1’624 subjects (563 men and 1061 women) with a lifetime history of 
MDD at baseline and the Non-Caucasians (n=168) because they had no measure of the tHcy 
concentration. Among the remaining 1’927 subjects, 24 died, 95 could not be traced and 134 
refused participation resulting in 1’674 subjects who took part in the somatic or the psychiatric 
follow-up evaluations (86.8% participation). Among them, 43 subjects were excluded due to 
missing information on depression at follow-up. The final sample therefore consisted of 1’631 
subjects (43.6% women; mean age: 51.7 years, s.d. 8.8 years). The mean follow-up duration 
was 5.2 years (s.d. 1.2 years), corresponding to 8’422 person-years. Compared to participants, 
non-participants at the follow-up had lower socio-economic status (SES; 61.2% vs. 52.7%, 
2=7.08, p=0.01), were less physically active (58.8% vs. 49.8%, 2=8.13, p=0.04), suffered from 
overweight more frequently (50.3% vs. 59.5%, 2=8.21, p=0.04), reported cardiovascular events 
more frequently (2.3% vs. 6.5%, 2=15.85, p<0.001) and were more frequently exposed to 
aspirin (8.1% vs. 13.8%, 2=9.68, p=0.002). Participants and non-participants also differed by 
the level of alcohol intake (22=9.60, p=0.01). 
The Institutional Ethics’ Committee of the University of Lausanne approved the CoLaus and 
subsequently the PsyCoLaus study. All participants signed a written informed consent after 
having received a description of the goal and funding of the study. 
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Measurements 
Depression status and comorbid mental disorders 
Diagnostic information on MDD at baseline and follow-up and comorbid anxiety and drug use 
disorders at baseline was collected using the French version (Leboyer et al., 1995) of the semi-
structured Diagnostic Interview for Genetic Studies (DIGS), which was developed and 
extensively validated by the National Institute of Mental Health (Nurnberger et al., 1994). The 
French version of this instrument also revealed adequate inter-rater and test-retest reliability for 
major mood (Preisig et al., 1999) and substance use disorders (Berney et al., 2002). The DIGS 
was completed with sections on generalized anxiety disorder and phobias using questions from 
the Schedule for Affective Disorders and Schizophrenia-Lifetime and Anxiety disorder version 
(SADS-LA (Endicott and Spitzer, 1978)), which also revealed satisfactory test-retest reliability 
(Leboyer et al., 1991; Rougemont-Buecking et al., 2008). At baseline lifetime diagnoses and at 
follow-up the diagnosis of MDD since baseline were assigned according to the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric 
Association, 2000). For the 162 individuals (9.9%) who were not willing to complete the DIGS 
interview at follow-up, MDD status at follow-up was determined using the Center for 
Epidemiologic Studies Depression Scale (CES-D) (Morin et al., 2011; Radloff, 1977). A score of 
19 or higher was considered as an indicator of the presence of a major depressive episode 
(MDE) (Morin et al., 2011; Radloff, 1977). Interviewers were required to be masters-level 
psychologists and were trained over a two-month period. In order to provide ongoing 
supervision throughout the study, each interview and diagnostic assignment was reviewed by 
an experienced senior psychologist. 
Aspirin and statin use and covariates 
The assessment of regular aspirin and statin use during the 6 months prior to the baseline and 
follow-up physical evaluations was based on the following two questions: 1) During the last 6 
months have you taken any prescribed drugs?; 2) During the last 6 months have you taken any 
non prescribed drugs, including vitamins, herbal medicines or dietary supplements? Participants 
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were then probed for the name of the drug, the reason and frequency of treatment (regular or 
occasional). Data were also collected on age, marital status and health-related behaviors at 
baseline including smoking (never, former and current), regular alcohol intake (units/week) and 
physical activity (no or low versus at least 20 minutes twice a week). Information on SES was 
derived from the DIGS and the level was assessed using the Hollingshead scale (Hollingshead, 
1975). The following biological variables were either measured during the baseline physical 
evaluation or based on readings from venous blood samples drawn after an overnight fast: 
overweight (BMI ≥ 25 kg/m2), high total cholesterol (≥ 6.2 mmol/l), high triglycerides (≥ 2.2 
mmol/l), hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 
mmHg, or drug treatment for hypertension), and diabetes (fasting blood glucose ≥ 7mmol/l or 
treatment for diabetes). Serum tHcy levels were determined with high performance liquid 
chromatography (Firmann et al., 2008). High tHcy levels were defined as concentrations ≥ 
15μmol/l (Almeida et al., 2012; Nabi et al., 2013). Finally, a lifetime history of CVD was defined 
as a cardiovascular event (myocardial infarction, coronary insufficiency or stroke) documented 
in the medical records.  
 
Statistical analysis 
Analyses were performed using the Statistical Analysis System (SAS Institute Inc., Cary, NC, 
USA), version 9.3, for Windows. Multiple imputations were used to avoid bias related to 
exclusion of subjects with missing values (Sterne et al., 2009). Using the Markov Chain Monte 
Carlo method, we created 100 complete datasets (Schafer, 1997; White et al., 2011). Each 
dataset was analyzed separately and results were combined using Rubin’s multiple imputation 
strategy (Rubin, 1987; Sterne et al., 2009). Univariate analyses were conducted using chi-
square or Fisher’s exact tests as appropriate. Proportional hazard models were applied 
(PHREG procedure (Cox, 1972)) to assess the associations between regular exposure to 
aspirin or statins at baseline and the incidence of MDD during the follow-up period with 
adjustment for socio-demographic, health-related and biological risk factors as well as comorbid 
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mental disorders. These models also tested interactions between the effects of sex and aspirin 
or statins. In subsequent analyses, associations were tested in subjects older than 50 years. 
The same models were applied to a restricted sample of subjects who had indicated regular use 
of aspirin or statins prior to both baseline and follow-up evaluations, versus non-users. In 
addition, associations were tested in the whole sample, including subjects who had reported 
MDD at baseline, using the models additionally adjusted for MDD at baseline. Finally, we aimed 
to test the potential effect of tHcy levels on the association between exposure to aspirin or 
statins and the incidence of MDD. 
 
Results 
The description of the prospective cohort of 1’631 subjects at baseline as a function of regular 
aspirin and statin use is presented in Table 1. Among these subjects, 45 were both regular 
aspirin and statin users, 87 were exposed to aspirin only and 92 to statins only during the six 
months prior to the baseline evaluation. Among the subjects exposed to statins, 40.2% used 
atorvastatin, 29.2% parvastatin, 24.8% simvastatin and 5.8% fluvastatin. The proportion of 
subjects who still used the drug regularly at follow-up was 50% for aspirin and 85% for statin 
users. Subjects exposed to aspirin and statins at baseline were older and more frequently 
overweight, had higher levels of triglycerides, experienced hypertension and diabetes more 
frequently, reported a history of CVD more frequently and reported drug use disorders less 
frequently than the other subjects. Users and non-users of aspirin and statins also differed by 
smoking status. In addition, regular statin users had lower SES and revealed a high total 
cholesterol level less frequently than the other subjects.  
 
During the follow-up period 84 (9.1%) out of the 920 men and 127 (17.9%) out of the 711 
women developed a first episode of MDD. As the proportional hazard model did not provide 
evidence for interactions between the effects of sex and aspirin (p=0.565) or statins (p=0.393) 
regarding the incidence of MDD, results for the whole sample are presented. The unadjusted 
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Hazard Ratios (HR) for regular exposure to aspirin and statins were 0.86 (95% C.I.: 0.51-1.45) 
and 0.93 (95% C.I.: 0.57-1.52), respectively. The results of the model with adjustment for 
covariates confirmed the absence of significant associations between aspirin and statin 
exposure and the development of MDD (Table 2). Among the covariates, diabetes and a lifetime 
history of anxiety disorders were predictors for the onset of MDD whereas older age (between 
55 and 66 years) and moderate or high alcohol consumption were negatively associated with 
the incidence of MDD. Despite the absence of significant interactions between sex and aspirin 
and statin exposure status, the results for men and women are also provided separately in 
Table 2 in order to assure comparability with the findings of previous studies (Almeida et al., 
2010; Almeida et al., 2012; Pasco et al., 2010).  
 
The results hardly changed when the cohort was reduced to subjects older than 50 years 
(n=801). Again, there were no significant associations between the incidence of MDD and 
regular exposure to aspirin (HR = 0.96; 95% C.I. 0.44 - 2.03) or statins (HR = 1.08; 95% C.I. 
0.55 - 2.12). Similarly, if exposure to aspirin or statins was restricted to those who indicated 
regular use of the drug prior to both the baseline and follow-up evaluations versus non-users 
(n=1’558), the HR for MDD in aspirin and statin users remained at 0.91 (95% C.I. 0.36 – 2.32) 
and 1.38 (95% C.I. 0.74 – 2.55), respectively. Moreover, using the incidence of a MDE during 
the follow-up period as the outcome variable in the whole sample of 2’830 subjects, the 
estimates of the effects of exposure to aspirin (HR=1.16; 95% C.I. 0.87 – 1.37) or statins 
(HR=0.96; 95% C.I. 0.67 – 1.37) hardly changed. In addition, we did not find any evidence for 
differential effects of specific types of statins on the risk of depression (results not shown here). 
 
Regarding the potential effect of tHcy levels on the associations, only 99 subjects in our cohort 
revealed tHcy concentrations ≥ 15μmol/l. Interestingly, none of the 20 subjects with regular 
exposure to aspirin or statins developed a MDE during follow-up, whereas 7 out of the 79 
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subjects (8.9%) without such treatment had suffered from depression during follow-up (p=0.19 
according to the Fisher’s exact test). 
 
Discussion 
Our data, based on a large 35 to 66 year-old cohort which was assessed using thorough 
physical and psychiatric evaluations at baseline and follow-up, did not provide evidence for a 
preventive effect of regular aspirin or statin use on the incidence of MDD over a more than five-
year follow-up period regardless of sex and age and after adjustment for a comprehensive array 
of potential confounders.  
The absence of an association between regular aspirin or statin use and MDD contrasts with 
prospective studies that observed a preventive effect of these drugs on depression (Pasco et 
al., 2010; Young-Xu et al., 2003; Parsaik et al., 2014; Redlich et al., 2014). The discrepant 
results between our findings and those of the Australian community study (Pasco et al., 2010), 
which was based on similar methods, is most likely attributable to differences between the two 
cohorts. Indeed, the Australian cohort had no upper age limit whereas ours only included 
subjects up to 66 years. Accordingly, the Australian cohort was likely to be composed of more 
physically affected subjects, which was reflected by the much higher mortality rate of 26.4% vs. 
only 1.5% in our study. It is therefore possible that the preventive effect of aspirin and statins on 
depression is restricted to elderly subjects who may already have CHD. Indeed, most evidence 
for a preventive effect of these anti-inflammatory drugs on depression stems from three studies 
on mostly elderly patients treated for CHD (Otte et al., 2012; Stafford and Berk, 2011; Young-Xu 
et al., 2003). Unfortunately, given that only 37 subjects of our cohort had a history of CHD we 
could not conduct analyses in this subsample. Similarly, the subsample of subjects with high 
tHcy levels was also too small to draw conclusions. However, the fact that none of the subjects 
with high tHcy levels and regular exposure to aspirin or statins developed a MDE during follow-
up was compatible with a potentially preventive effect of these drugs in more severely affected 
subjects. Alternatively, bias due to differential survival effects (e.g. if depression is more strongly 
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associated with mortality among treated subjects, who are more likely to suffer CHD, than 
among non-treated subjects) could also at least partially explain the association between ant-
inflammatory drug use and the reduced risk of depression in more severely affected elderly 
cohorts. Interestingly, none of the RCTs that assessed depression symptoms (While and Keen, 
2012) provided evidence for a reduction of depressive symptoms under statin treatment in 
mostly younger patients, which is compatible with our findings. Nevertheless, drugs that prevent 
the incidence of new depressive disorders do not necessarily need to reduce the level of 
existing depressive symptoms during treatment. The recent register-based Swedish study 
(Redlich et al. 2014), which however was not based on structured diagnostic interviews, 
suggested that inconsistent results of previous research could be attributable to differential 
effects of specific types of statins on depression. However, our data provide no evidence for this 
hypothesis.  
Our findings have important implications for treatment and future research. Together with the 
results of RCTs our data do not support a large scale preventive treatment of depression using 
aspirin or statins in subjects aged 35 to 66 years from the community. However, our data cannot 
preclude such an effect in subjects older than 66 years of age or in patients with CHD. 
Interestingly, in our relatively healthy cohort previous analyses did not provide evidence for an 
impact of low-dose aspirin use on pro-inflammatory cytokine or high-sensitive C-reactive protein 
levels, either (Vaucher et al., 2014).  
The results of the present study should be considered in the context of several limitations. First, 
our study was not a RCT and therefore it is likely that the analyses could not adjust for all 
confounding factors that were unequally distributed between treated and untreated subjects. 
Second, information on regular aspirin or statin use was collected only for the 6 months prior to 
the baseline and follow-up evaluations and therefore information on treatment status throughout 
the follow-up was missing. Moreover, we did not measure compliance to treatment. Third, the 
sample was restricted to subjects between 35 and 66 years of age, which impedes conclusions 
regarding the preventive effects of aspirin or statins in young adults and in subjects older than 
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66 years. Moreover, the sample was recruited in an urban area. However, although the 
particular features of the sample may affect the likelihood of anti-inflammatory treatment and the 
prevalence of depression, it is less likely that they significantly affect the prospective association 
between this treatment and the incidence of MDD. Fourth, for 162 subjects (10%) information on 
depression during the follow-up was collected using the CES-D depression scale rather than the 
semi-structured interview. However, the HRs (aspirin: HR = 1.17; 95% C.I. 0.66 - 2.09; statins: 
HR = 1.26; 95% C.I. 0.71 - 2.22) did not change after exclusion of these subjects. Fifth, 
although more than 200 subjects developed MDD during follow-up our sample was too small to 
test differential effects of regular aspirin or statin use on depression subtypes. Indeed, given the 
well-known large heterogeneity of MDD and findings on differential associations between its 
subtypes and CVRFs/CVD (Glaus et al., 2013; Penninx et al., 2013), exposure to anti-
inflammatory drugs may reveal differential associations with specific MDD subtypes. 
To conclude, our findings do not support a preventive effect of regular aspirin or statin use on 
MDD in 35 to 66 year-old adults from the community. However, the effects of these anti-
inflammatory drugs in more severely affected or older subjects could not be appropriately tested 
in this cohort. Accordingly, in these subjects the completion of large-scale RCTs in order to 
further assess the potentially preventive effect of these drugs on the incidence of depression is 
likely to be more warranted than in relatively healthy community samples. 
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Table 1: Baseline characteristics of participants as a function of aspirin and statin use 
(n=1’631) 
Characteristics 
Aspirin use   Statin use 
Yes No Yes No 
n = 132 n =1’499 n = 137 n = 1’494 
% % p-valuea   % % p-valuea 
Sociodemographics               
Gender        
Women vs Men 46.21 43.36 .527  35.77 44.31 .054 
Age (years)        
35-45 15.15 33.56 
<.0001 
 5.84 34.47 
<.0001 45-54 21.21 33.96  24.82 33.67 
55-66 63.64 32.49  69.34 31.86 
Socio-economic status        
High vs Low 51.52 46.90 .308  37.96 48.13 .023 
Marital status        
Married vs Others 60.61 65.04 .307  67.88 64.39 .413 
Health-related behaviors        
Smoking status        
Never 39.39 41.63 
.011 
 29.93 42.50 
.006 Former 43.94 32.42  44.53 32.33 
Current 16.67 25.95  25.55 25.17 
Alcohol intake        
No 25.00 21.75 
.664 
 21.90 22.02 
.902 Low 57.58 59.11  57.66 59.10 
Moderate or high 17.42 19.15  20.44 18.88 
Physical activity        
≥ 20 min ≥ 2/week 57.58 58.91 .766  53.28 59.30 .171 
Biological risk factors        
Overweight 69.70 48.63 <.0001  79.56 47.66 <.0001 
Total cholesterol ≥ 6.2 mmol/l 15.91 23.22 .054  15.33 23.29 .033 
Triglycerides ≥ 2.2 mmol/l 18.94 11.81 .017  28.47 10.91 <.0001 
Hypertension 57.58 29.29 <.0001  56.20 29.32 <.0001 
Homocystein 8.33 5.87 .256  9.49 5.76 .080 
Diabetes 15.15 4.54 <.0001  18.98 4.15 <.0001 
History of CVD 21.21 0.60 <.0001  15.33 1.07 <.0001 
Comorbid mental disorders        
Anxiety disorders 13.64 13.53 .973  15.44 13.36 .498 
Drug use disorders 0.76 5.42 .012b  0.74 5.43 .012
b 
Statistically significant results are in bold.  
a Chi-Square test.  
b Fisher's Exact test.  
Alcohol intake: low (1-6 units/week), moderate (7-13 units/week) or high (14 or more units/week). 
Abbreviation: CVD= cardiovascular disease.  
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Table 2: Fully adjusted hazard ratios (HR) for the incidence of major depressive disorder 
according to aspirin and statin use (n=1’631) 
 Major depressive disorder 
  All (n=1’631)   Men (n=920)   Women (n=711) 
  HR  95% CI   HR  95% CI   HR  95% CI 
Aspirin and statins         Aspirin 1.19 (0.68-2.08)  1.56 (0.63-3.88)  0.83 (0.40-1.74) Statins 1.25 (0.73-2.14)  1.56 (0.72-3.35)  0.94 (0.41-2.14) Sociodemographics                 
Age (years)         
35-45 1 (Reference)  1 (Reference)  1 (Reference) 
45-54 0.90 (0.66-1.24)  0.81 (0.49-1.32)  0.95 (0.62-1.45) 
55-66 0.55 (0.37-0.81)**  0.41 (0.21-0.82)*  0.57 (0.33-0.95)* 
Socio-economic status         High vs Low 0.93 (0.70-1.23)  0.91 (0.58-1.42)  0.99 (0.69-1.43) 
Marital status         Married vs Others 0.75 (0.56-1.01)  0.84 (0.50-1.40)  0.82 (0.57-1.19) 
Health-related behaviors                 
Smoking status         
Never 1 (Reference)  1 (Reference)  1 (Reference) 
Former 1.16 (0.83-1.62)  0.96 (0.55-1.66)  1.28 (0.84-1.96) Current 1.31 (0.92-1.87)  1.49 (0.84-2.65)  1.17 (0.74-1.86) 
Alcohol intake         
No 1 (Reference)  1 (Reference)  1 (Reference) 
Low 0.94 (0.68-1.30)  1.40 (0.74-2.66)  0.84 (0.56-1.24) 
Moderate or high 0.52 (0.31-0.86)*  0.76 (0.34-1.68)  0.66 (0.30-1.46) 
Physical activity         ≥ 20 min ≥ 2/week 1.16 (0.87-1.54)  1.49 (0.93-2.36)  0.94 (0.65-1.37) 
Biological risk factors                 
Overweight 0.99 (0.74-1.33)  1.30 (0.80-2.10)  1.02 (0.68-1.52) Total cholesterol ≥ 6.2 mmol/l 1.15 (0.81-1.64)  1.28 (0.75-2.19)  1.06 (0.65-1.72) Triglycerides ≥ 2.2 mmol/l 0.79 (0.49-1.29)  1.04 (0.57-1.90)  0.59 (0.23-1.51) 
Hypertension 0.77 (0.54-1.11)  0.64 (0.36-1.13)  0.93 (0.58-1.48) Homocystein 0.65 (0.30-1.38)  0.46 (0.14-1.48)  0.94 (0.34-2.58) 
Diabetes 1.86 (1.02-3.39)*  2.27 (1.04-4.93)*  2.81 (0.99-8.02) 
History of CVD 0.22 (0.03-1.64)  0.34 (0.04-2.87)  
a -- -- 
Comorbid mental disorders                 
Anxiety disorders 1.70 (1.22-2.37)**  1.98 (1.13-3.46)*  1.40 (0.92-2.14) 
Drug use disorders 1.24 (0.72-2.13)  0.98 (0.43-2.23)  1.94 (0.92-4.11) Statistically significant results are in bold: ** p<.01; * p<.05. 
Hazard ratios from a single model adjusted for all covariates in the table. 
 a Model could not be computed due to small sample size. 
Alcohol intake: low (1-6 units/week), moderate (7-13 units/week) or high (14 or more units/week).  
Abbreviations: HR=hazard ratio, CI= confidence interval, CVD= cardiovascular disease.  
 
 
